Speaker Profile
Ph.D., CEO, L7 Informatics
Biography
Vasu Rangadass, Ph.D., is the CEO of L7 Informatics, a company that delivers software and services enabling DATA+INTELLIGENCE for science and health. Since joining L7, Dr. Rangadass has led the further development of the Enterprise Science Platform (L7ESP), a cutting-edge scientific process and data management solution that empowers life science and healthcare organizations to connect people, processes, and systems, accelerating discoveries and advancing precision healthcare.Prior to L7 Informatics, Dr. Rangadass served as Chief Strategy Officer at NantHealth, following its acquisition of Net.Orange, the company he founded. Net.Orange provided an enterprise-wide platform, the Clinical Operating System (cOS), designed to simplify and optimize care delivery processes within health systems. With a rich background in digital health and a passion for transforming healthcare through innovative technology, Dr. Rangadass continues to lead initiatives that drive impactful change in the industry.
Talk
Accelerating Precision Medicine with Unified Platforms
Discover how L7ESP transforms precision medicine by offering data contextualization at the point of execution. Learn how this capability supports successful AI integration, enhances efficiency, and drives rapid breakthroughs. Optimize your approach to drug development and personalized treatments with advanced data orchestration and contextualization.
AI and Data Sciences Showcase:
L7 Informatics, Inc.
L7 Informatics, Inc. is a leading provider of integrated scientific data and analytics solutions. The company offers a comprehensive platform that enables seamless data integration, advanced analytics, and collaborative workflows, empowering scientists and researchers to accelerate discoveries, improve operational efficiencies, and drive innovation.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2024 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
